(PSYCHIATRIC TIMES) - MedPage Today Action Points
NEW YORK, Jan. 18 -- Gauging the winds of medical advances is an iffy proposition at best, but for psychiatrists the new year is likely to bring much-anticipated data on the safety and efficacy of antipsychotic and bipolar medications in children and adolescents.
With pediatric safety and efficacy data lacking for most drugs used to treat schizophrenia and bipolar disorder, use of these drugs in pediatric patients is more off-label than on-label, noted Christoph U. Correll, of the Albert Einstein College of Medicine in the Bronx. Dr. Correll is also a member of the American Academy of Child and Adolescent Psychiatry (AACAP).
For full article, please visit: